Patent: 7,638,335
✉ Email this page to a colleague
Summary for Patent: 7,638,335
Title: | Kit comprising antihuman TNF-.alpha. antibody and antihuman TNF-.alpha. antibody activity lowering inhibitor |
Abstract: | The present invention provides an antihuman TNF-.alpha. antibody activity lowering inhibitor comprising a protein source(s) and/or carbohydrate source(s), in the treatment of inflammatory bowel syndrome with repeated administration of anti-TNF-.alpha. antibody; and a kit preparation wherein a freeze-dried antihuman TNF-.alpha. antibody and the activity lowering inhibitor in the above repeated administration of the anti-TNF-.alpha. antibody are separately contained in a plastic container so that they can communicate with each other. According to the present invention, in the drug therapy to the patients with inflammatory bowel syndrome, therapeutic agents which inhibit the inflammation for long periods without accompanying serious side effects can be provided. |
Inventor(s): | Matsumoto; Takayuki (Fukuoka, JP) |
Assignee: | AJINOMOTO Co., Inc. (Tokyo, JP) |
Application Number: | 11/514,225 |
Patent Claims: | see list of patent claims |
Details for Patent 7,638,335
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2024-03-01 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2024-03-01 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2024-03-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |